Evidence map›Paper›PMID 35773744›Full record

ArticleMolecular cancer2022

CircEZH2/miR-133b/IGF2BP2 aggravates colorectal cancer progression via enhancing the stability of m

Bing Yao, Qinglin Zhang, Zhou Yang, Fangmei An, He Nie, Hui Wang, Cheng Yang, Jing Sun, Ke Chen, Jingwan Zhou and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 1 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Bing Yao *Departments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu Province, China. byao@njmu.edu.cn.ORCID 0000-0002-6657-2760
Qinglin Zhang *Departments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu Province, China.
Zhou Yang *Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Fangmei AnDepartments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu Province, China.
He NieDepartments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu Province, China.
Hui WangDepartments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu Province, China.
Cheng YangDepartments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu Province, China.
Jing SunDepartments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu Province, China.
Ke ChenDepartments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu Province, China.
Jingwan ZhouDepartments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu Province, China.
Bing BaiCenter for Precision Medicine, Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province, China.
Shouyong GuInstitute of Geriatric Medicine, Jiangsu Province Geriatric Hospital, Nanjing, Jiangsu Province, China. gushouyong@jspgh.com.
Wei ZhaoDepartment of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong, China. wzhao42@cityu.edu.hk.
Qiang ZhanDepartments of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Department of Medical Genetics, Nanjing Medical University, Nanjing, Jiangsu Province, China. ryzhanqiang@njmu.edu.cn.
Wuxi People's Hospital · CNCity University of Hong Kong · HKFudan University Shanghai Cancer Center · CNJiangsu Province Hospital · CNNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAberrant expression of circular RNAs (circRNAs) contributes to the initiation and progression of human malignancies, but the underlying mechanisms remain largely elusive.

methodsHigh-throughput sequencing was performed to screen aberrantly expressed circRNAs or miRNAs in colorectal cancer (CRC) and adjacent normal tissues. A series of gain- and loss-of-function studies were conducted to evaluate the biological behaviors of CRC cells. RNA pulldown, mass spectrometry, RIP, qRT-PCR, Western blot, luciferase reporter assays and MeRIP-seq analysis were further applied to dissect the detailed mechanisms.

resultsHere, a novel circRNA named circEZH2 (hsa_circ_0006357) was screened out by RNA-seq in CRC tissues, whose expression is closely related to the clinicpathological characteristics and prognosis of CRC patients. Biologically, circEZH2 facilitates the proliferation and migration of CRC cells in vitro and in vivo. Mechanistically, circEZH2 interacts with m

conclusionsOur findings not only reveal the pivotal roles of circEZH2 in modulating CRC progression, but also advocate for attenuating circEZH2/miR-133b/IGF2BP2/ CREB1 regulatory axis to combat CRC.

Indexed as

Colorectal NeoplasmsCyclic AMP Response Element-Binding ProteinMicroRNAsRNA-Binding ProteinsRNA, CircularCell Line, TumorHumansRNA, MessengerCREB1 protein, humanCyclic AMP Response Element-Binding ProteinIGF2BP2 protein, humanMicroRNAsMIRN133 microRNA, humanRNA-Binding ProteinsRNA, CircularRNA, MessengerCircEZH2Colorectal cancerCREB1IGF2BP2miR-133b

Identifiers

PMID35773744
PMCPMC9245290
OpenAlexW4283724601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.